A low COMT activity haplotype is associated with recurrent preeclampsia in a Norwegian population cohort (HUNT2)

Molecular Human Reproduction

Volumn 17, Issue 7, 2011, Pages 439-446

  Roten, L T ^a   Fenstad, M H ^a   Forsmo, S ^b   Johnson, M P ^c   Moses, E K ^c   Austgulen, R ^a   Skorpen, F ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

158Met; Catechol O methyltransferase; COMT; Haplotypes; Preeclampsia; Val108

Indexed keywords

CATECHOL METHYLTRANSFERASE;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE ACTIVITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; NORWAY; OXIDATIVE STRESS; PREECLAMPSIA; PRIORITY JOURNAL; RECURRENT DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM;

CATECHOL O-METHYLTRANSFERASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; NORWAY; PRE-ECLAMPSIA; PREGNANCY;

EID: 79959449593     PISSN: 13609947     EISSN: 14602407     Source Type: Journal    
DOI: 10.1093/molehr/gar014     Document Type: Article

References (69)

1. Andersen S, Skorpen F. Variation in the COMT gene: implications for pain perception and pain treatment. Pharmacogenomics 2009;10:669-684.
2. Annerbrink K, Westberg L, Nilsson S, Rosmond R, Holm G, Eriksson E. Catechol O-methyltransferase val158-met polymorphism is associated with abdominal obesity and blood pressure in men. Metabolism 2008; 57:708-711.
3. Azzam A, Mathews CA. Meta-analysis of the association between the catecholamine-O-methyl-transferase gene and obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet 2003;123B:64-69.
4. Banerjee S, Randeva H, Chambers AE. Mouse models for preeclampsia: disruption of redox-regulated signaling. Reprod Biol Endocrinol 2009;7:4.
5. Barchiesi F, Jackson EK, Fingerle J, Gillespie DG, Odermatt B, Dubey RK. 2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle. Circ Res 2006;99:266-274.
6. Barnea ER, MacLusky NJ, DeCherney AH, Naftolin F. Catechol-O-methyl transferase activity in the human term placenta. Am J Perinatol 1988; 5:121-127.
7. Bray NJ, Buckland PR, Williams NM, Williams HJ, Norton N, Owen MJ, O'Donovan MC. A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am J Hum Genet 2003;73:152-161.
8. Broughton Pipkin F. What is the place of genetics in the pathogenesis of pre-eclampsia? Biol Neonate 1999;76:325-330.
9. Casey ML, MacDonald PC. Characterization of catechol-O-methyltransferase activity in human uterine decidua vera tissue. Am J Obstet Gynecol 1983; 145:453-457.
10. Chappell S, Morgan L. Searching for genetic clues to the causes of pre-eclampsia. Clin Sci (Lond) 2006;110:443-458.
11. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, Kolachana BS, Hyde TM, Herman MM, Apud J et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004;75:807-821.
12. Ciaccio M, Bellia C. Hyperhomocysteinemia and cardiovascular risk: effect of vitamin supplementation in risk reduction. Curr Clin Pharmacol 2010; 5:30-36.
13. Consortium G. Disentangling fetal and maternal susceptibility for pre-eclampsia: a British multicenter candidate-gene study. Am J Hum Genet 2005;77:127-131.
14. Creveling CR. Reduced COMT activity as a possible environmental risk factor for breast cancer. Opin Neurotox Res 2003;5:473-474.
15. Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I, Goldman D, Xu K, Shabalina SA, Shagin D et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 2005;14:135-143.
16. Dubey RK, Jackson EK. Potential vascular actions of 2-methoxyestradiol. Trends Endocrinol Metab 2009;20:374-379.
17. Dubey RK, Imthurn B, Jackson EK. 2-Methoxyestradiol: a potential treatment for multiple proliferative disorders. Endocrinology 2007; 148:4125-4127.
18. Eriksson AL, Skrtic S, Niklason A, Hulten LM, Wiklund O, Hedner T, Ohlsson C. Association between the low activity genotype of catechol-O-methyltransferase and myocardial infarction in a hypertensive population. Eur Heart J 2004;25:386-391.
19. Fenstad MH, Johnson MP, Loset M, Mundal SB, Roten LT, Eide IP, Bjorge L, Sande RK, Johansson AK, Dyer TD et al. STOX2 but not STOX1 is differentially expressed in decidua from pre-eclamptic women: data from the Second Nord-Trøndelag Health Study. Mol Hum Reprod 2010;16:960-968.
20. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L. The endogenous oestrogen metabolite 2-methoxyoest radiol inhibits angiogenesis and suppresses tumour growth. Nature 1994; 368:237-239.
21. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-2229.
22. Gifford RW, August PA, Cunningham G, Green LA, Lindheimer MD, McNellis D, Roberts JM, Sibai BM, Taler SJ. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000;183:S1-S22.
23. Guven MA, Coskun A, Ertas IE, Aral M, Zencirci B, Oksuz H. Association of maternal serum CRP, IL-6, TNF-alpha, homocysteine, folic acid and vitamin B12 levels with the severity of preeclampsia and fetal birth weight. Hypertens Pregnancy 2009;28:190-200.
24. Hagen K, Pettersen E, Stovner LJ, Skorpen F, Holmen J, Zwart JA. High systolic blood pressure is associated with Val/Val genotype in the catechol-O-methyltransferase gene. The Nord-Trøndelag Health Study (HUNT). Am J Hypertens 2007a;20:21-26.
25. Hagen K, Stovner LJ, Skorpen F, Pettersen E, Zwart JA. The impact of the catechol-O-methyltransferase Val158Met polymorphism on survival in the general population-the HUNT study. BMC Med Genet 2007b;8:34.
26. Halleland H, Lundervold AJ, Halmoy A, Haavik J, Johansson S. Association between catechol O-methyltransferase (COMT) haplotypes and severity of hyperactivity symptoms in adults. Am J Med Genet B Neuropsychiatr Genet 2009;150B:403-410.
27. Happonen P, Voutilainen S, Tuomainen TP, Salonen JT. Catechol-Omethyltransferase gene polymorphism modifies the effect of coffee intake on incidence of acute coronary events. PLoS ONE 2006;1:e117.
28. Harirah H, Thota C, Wentz MJ, Zaman W, Al-Hendy A. Elevated expression of catechol-O-methyltransferase is associated with labor and increased prostaglandin E(2) production by human fetal membranes. Am J Obstet Gynecol 2009;201:496 e1-7.
29. Hildrum B, Mykletun A, Hole T, Midthjell K, Dahl AA. Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study. BMC Public Health 2007;7:220.
30. Hintsanen M, Elovainio M, Puttonen S, Kivimaki M, Lehtimaki T, Kahonen M, Juonala M, Rontu R, Viikari JS, Raitakari OT et al. Val/Met polymorphism of the COMT gene moderates the association between job strain and early atherosclerosis in young men. J Occup Environ Med 2008;50:649-657.
31. Holmen J, Midthjell K, Krüger Ø, Langhammer A, Holmen TL, Bratberg GH, Vatten L, Lund-Larsen PG. The Nord-Trøndelag Health Study 1995-97 (HUNT 2): objectives, contents, methods and participation. Nor J Epidemiol 2003;13:19-32.
32. Holmen J, Kjelsaas M, Krüger Ø, Ellekjær H, Ross G, Holmen T, Midthjell K, Stavnas P, Krokstad S. Attitudes to genetic epidemiology-illustrated by questions for re-consent to 61,426 participants at HUNT. Nor J Epidemiol 2004;14:27-31.
33. Kanasaki K, Kalluri R. The biology of preeclampsia. Kidney Int 2009; 76:831-837.
34. Kanasaki K, Palmsten K, Sugimoto H, Ahmad S, Hamano Y, Xie L, Parry S, Augustin HG, Gattone VH, Folkman J et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature 2008;453:1117-1121.
35. Lalouel JM, Rohrwasser A. Power and replication in case-control studies. Am J Hypertens 2002;15:201-205.
36. LaVallee TM, Zhan XH, Johnson MS, Herbstritt CJ, Swartz G, Williams MS, HembroughWA, Green SJ, Pribluda VS. 2-Methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res 2003;63:468-475.
37. Lee SB, Wong AP, Kanasaki K, Xu Y, Shenoy VK, McElrath TF, Whitesides GM, Kalluri R. Preeclampsia: 2-methoxyestradiol induces cytotrophoblast invasion and vascular development specifically under hypoxic conditions. Am J Pathol 2010;176:710-720.
38. Lim JH, Kim SY, Kim DJ, Park SY, Han HW, Han JY, Lee SW, Yang JH, Ryu HM. Genetic polymorphism of catechol-O-methyltransferase andcytochrome P450c17 in preeclampsia. Pharmacogenet Genomics 2010; 20:605-610.
39. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I, Taskinen J. Kinetics of human soluble and membrane-bound catechol O-methyl transferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995;34:4202-4210.
40. Magnussen EB, Vatten LJ, Smith GD, Romundstad PR. Hypertensive disorders in pregnancy and subsequently measured cardiovascular risk factors. Obstet Gynecol 2009;114:961-970.
41. Marsal K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Paediatr 1996;85:843-848.
42. Mignini LE, Latthe PM, Villar J, Kilby MD, Carroli G, Khan KS. Mapping the theories of preeclampsia: the role of homocysteine. Obstet Gynecol 2005;105:411-425.
43. Moses EK, Fitzpatrick E, Freed KA, Dyer TD, Forrest S, Elliott K, Johnson MP, Blangero J, Brennecke SP. Objective prioritization of positional candidate genes at a quantitative trait locus for pre-eclampsia on 2q22. Mol Hum Reprod 2006;12:505-512.
44. Moses EK, Johnson MP, Tommerdal L, Forsmo S, Curran JE, Abraham LJ, Charlesworth JC, Brennecke SP, Blangero J, Austgulen R. Genetic association of preeclampsia to the inflammatory response gene SEPS1. Am J Obstet Gynecol 2008;198:336 e1-5.
45. Mutze S, Rudnik-Schoneborn S, Zerres K, Rath W. Genes and the preeclampsia syndrome. J Perinat Med 2008;36:38-58.
46. Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, Maixner W, Diatchenko L. Human catechol-O-methyl transferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006;314:1930-1933.
47. Nackley AG, Shabalina SA, Lambert JE, Conrad MS, Gibson DG, Spiridonov AN, Satterfield SK, Diatchenko L. Low enzymatic activity haplotypes of the human catechol-O-methyltransferase gene: enrichment for marker SNPs. PLoS ONE 2009;4:e5237.
48. Nejatizadeh A, Stobdan T, Malhotra N, Pasha MA. The genetic aspects of pre-eclampsia: achievements and limitations. Biochem Genet 2008; 46:451-479.
49. Ntaios G, Savopoulos C, Grekas D, Hatzitolios A. The controversial role of B-vitamins in cardiovascular risk: an update. Arch Cardiovasc Dis 2009; 102:847-854.
50. Odegard RA, Vatten LJ, Nilsen ST, Salvesen KA, Austgulen R. Preeclampsia and fetal growth. Obstet Gynecol 2000;96:950-955.
51. Prasad SE, Howley S, Murphy KC. Candidate genes and the behavioral phenotype in 22q11.2 deletion syndrome. Dev Disabil Res Rev 2008; 14:26-34.
52. Rakvag TT, Ross JR, Sato H, Skorpen F, Kaasa S, Klepstad P. Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol Pain 2008;4:64.
53. Ray JG, Laskin CA. Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: a systematic review. Placenta 1999;20:519-529.
54. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 2001;357:53-56.
55. Saftlas AF, Olson DR, Franks AL, Atrash HK, Pokras R. Epidemiology of preeclampsia and eclampsia in the United States, 1979-1986. Am J Obstet Gynecol 1990;163:460-465.
56. Salonen Ros H, Lichtenstein P, Lipworth L, Cnattingius S. Genetic effects on the liability of developing pre-eclampsia and gestational hypertension. Am J Med Genet 2000;91:256-260.
57. Sanchez SE, Zhang C, Rene Malinow M, Ware-Jauregui S, Larrabure G, Williams MA. Plasma folate, vitamin B(12), and homocyst(e)ine concentrations in preeclamptic and normotensive Peruvian women. Am J Epidemiol 2001;153:474-480.
58. Semenza GL. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev 1998;8:588-594.
59. Shenoy V, Kanasaki K, Kalluri R. Pre-eclampsia: connecting angiogenic and metabolic pathways. Trends Endocrinol Metab 2010;21: 529-536.
60. Shibata K, Diatchenko L, Zaykin DV. Haplotype associations with quantitative traits in the presence of complex multilocus and heterogeneous effects. Genet Epidemiol 2009;33:63-78.
61. Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol 1991;165:1408-1412.
62. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73:1162-1169.
63. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68:978-989.
64. Terwilliger JD, Goring HH. Gene mapping in the 20th and 21st centuries: statistical methods, data analysis, and experimental design. Hum Biol 2000;72:63-132.
65. Tunbridge EM, Lane TA, Harrison PJ. Expression of multiple catechol-O-methyltransferase (COMT) mRNA variants in human brain. Am J Med Genet B Neuropsychiatr Genet 2007;144B:834-839.
66. Voutilainen S, Tuomainen TP, Korhonen M, Mursu J, Virtanen JK, Happonen P, Alfthan G, Erlund I, North KE, Mosher MJ et al. Functional COMT Val158Met polymorphism, risk of acute coronary events and serum homocysteine: the kuopio ischaemic heart disease risk factor study. PLoS ONE 2007;2:e181.
67. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995;92:5510-5514.
68. Woo JM, Yoon KS, Yu BH. Catechol O-methyltransferase genetic polymorphism in panic disorder. Am J Psychiatry 2002;159: 1785-1787.
69. Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, Koeppe RA, Stohler CS, Goldman D. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 2003; 299:1240-1243.